NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED).

Globus Medical, Inc. (GMED) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home page ...

Global M&A activity surged 15% year-over-year in Q1 2025, led by technology, financials, and energy sectors, signaling robust dealmaking momentum. Private equity remains a key driver, with record ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Globus Medical, Inc. (NYSE: GMED) has reported a significant increase in its sales for the fourth quarter and full year ending December 31, 2023. The company anticipates fourth quarter 2023 sales of ...